SBIR TOPIC 294 PHASE 1 - DEVELOPMENT OF GLYCOSYLATION - SPECIFIC RESEARCH

Information

  • Research Project
  • 8354002
  • ApplicationId
    8354002
  • Core Project Number
    261201100079C-1-0-1
  • Full Project Number
    261201100079C-1-0-1
  • Serial Number
    0
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/2011 - 13 years ago
  • Project End Date
    6/14/2012 - 12 years ago
  • Program Officer Name
  • Budget Start Date
    -
  • Budget End Date
    -
  • Fiscal Year
    2011
  • Support Year
  • Suffix
  • Award Notice Date
    -

SBIR TOPIC 294 PHASE 1 - DEVELOPMENT OF GLYCOSYLATION - SPECIFIC RESEARCH

The long term objectives of this proposal are to demonstrate the utility of a new class of high-specificity high-affinity proteins called Lectenz[unreadable] as research reagents for use in recognition of disease- or cancer-related glycosylation sites. The specific aims are to create a reagent that is pan-specific for the detection of the glycan f3-0-GlcNAc itself, as well as variations of this reagent that are able to detect f3-0-GIcNAc in the context of its disease- or cancer-specific peptide sequence (glycosylation site). The ability to rapidly confirm the presence of f3-0-GlcNAc in proteins and tissues without the need to turn to more-elaborate techniques would provide a powerful tool to delineate differentially glycosylated proteins and eventually establish correlations between f3-0-GIcNAc regulation and associated disease states, such as cancer. Using a combination of point mutagenesis, display library screening, and forefront computational methods, the human enzyme O-GIcNAcase (hOGA) will be converted into a high-specificity biosensor for its natural substrate f3-0-GIcNAc. Lectenz[unreadable] have several potential advantages over antibodies or aptamers, including predefined specificity for the target antigen, ease of preparation in a monovalent form, and (for human homologs) a low probability of in vivo toxicity. The innovative use of computational methods results in efficiency gains in the design and screening of the display library, lowering costs and increasing success rates.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    N43
  • Administering IC
    CA
  • Application Type
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    148851
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:148851\
  • Funding Mechanism
    Contracts, Extramural
  • Study Section
  • Study Section Name
  • Organization Name
    GLYCOSENSORS AND DIAGNOSTICS, LLC
  • Organization Department
  • Organization DUNS
    808436633
  • Organization City
    ATHENS
  • Organization State
    GA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    306021514
  • Organization District
    UNITED STATES